Cargando…
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335097/ https://www.ncbi.nlm.nih.gov/pubmed/35354254 http://dx.doi.org/10.3324/haematol.2021.280501 |
| _version_ | 1784759258556923904 |
|---|---|
| author | Kockerols, Camille C.B. Geelen, Inge Levin, Mark-David Janssen, Jeroen J.W.M. Dinmohamed, Avinash G. Hoogendoorn, Mels Cornelissen, Jan J. Westerweel, Peter E. |
| author_facet | Kockerols, Camille C.B. Geelen, Inge Levin, Mark-David Janssen, Jeroen J.W.M. Dinmohamed, Avinash G. Hoogendoorn, Mels Cornelissen, Jan J. Westerweel, Peter E. |
| author_sort | Kockerols, Camille C.B. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9335097 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93350972022-08-26 The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era Kockerols, Camille C.B. Geelen, Inge Levin, Mark-David Janssen, Jeroen J.W.M. Dinmohamed, Avinash G. Hoogendoorn, Mels Cornelissen, Jan J. Westerweel, Peter E. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-03-31 /pmc/articles/PMC9335097/ /pubmed/35354254 http://dx.doi.org/10.3324/haematol.2021.280501 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Kockerols, Camille C.B. Geelen, Inge Levin, Mark-David Janssen, Jeroen J.W.M. Dinmohamed, Avinash G. Hoogendoorn, Mels Cornelissen, Jan J. Westerweel, Peter E. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title | The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title_full | The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title_fullStr | The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title_full_unstemmed | The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title_short | The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| title_sort | use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335097/ https://www.ncbi.nlm.nih.gov/pubmed/35354254 http://dx.doi.org/10.3324/haematol.2021.280501 |
| work_keys_str_mv | AT kockerolscamillecb theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT geeleninge theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT levinmarkdavid theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT janssenjeroenjwm theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT dinmohamedavinashg theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT hoogendoornmels theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT cornelissenjanj theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT westerweelpetere theuseofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT kockerolscamillecb useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT geeleninge useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT levinmarkdavid useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT janssenjeroenjwm useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT dinmohamedavinashg useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT hoogendoornmels useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT cornelissenjanj useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera AT westerweelpetere useofhydroxyureapretreatmentinchronicmyeloidleukemiainthecurrenttyrosinekinaseinhibitorera |